myok - what happened to Maverick HCM trial planned to study non-obstructive HCM mentioned in last years PR? That would be a much larger potential market than oHCM. I also wonder if N of 200-250 is big enough to address uncertainty wrt AF recurrence or initiation. HCM patients have around 2% incidence of AF per year. People with AF 12 months prior or on certain AADs were excluded in Pioneer.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.